- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00361634
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis
DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The current literature shows the promise of magnetic resonance imaging (MRI) for assessing response to therapy in RA but the heterogeneity of the methodology and the semi-quantitative nature of the image analysis limits its applicability. To evaluate the ability of DCE-MRI to serve as a biomarker for treatment-induced changes in RA associated synovial inflammation, the reproducibility of the measurement and an effect size are required. Additional endpoints such as synovial volume, bone erosion progression and bone marrow edema-like changes may also prove useful for short-term assessment of a therapeutic intervention, but have not been explored in the context of a pharmacodynamic biomarker. It is therefore critical to conduct a carefully designed longitudinal study, focused on identifying the key parameters related to the instrumentation and data analysis, to fully evaluate the potential utility of MRI in an early clinical development setting. Importantly, this study will also demonstrate the feasibility of using DCE-MRI at multiple centers to acquire useful information that will drive program decisions.
Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen Call Center (866-572-6436) for more information.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
Los Angeles, California, Vereinigte Staaten
- Research Site
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten
- Research Site
-
-
-
-
-
London, Vereinigtes Königreich
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Fulfillment of the 1987 American College of Rheumatology (ACR) criteria for RA with a disease duration > 6 months
- Presence of active disease (defined as both tender and swollen joints) in at least one wrist
- Sub-optimal response to methotrexate (MTX) defined by the presence of the following criteria (based on 68/66 joint count): 8 or more swollen joints AND 8 or more tender joints (with involvement of the wrist, fingers and at least one region outside the hands) at screening
- Must be receiving MTX at a stable dose > 15 mg/week at least 12 weeks prior to baseline
- a lower dose is acceptable if otherwise not tolerated (toxicity documentation required).
Exclusion Criteria:
- Patients who are currently receiving disease modifying anti-rheumatic drug (DMARD) therapy (other than MTX, hydroxychloroquine or sulfasalazine) including tumor necrosis factor (TNF) antagonists (etanercept, infliximab, and adalimumab), abatacept, rituximab, leflunomide, cyclosporine, and gold (oral and intramuscular injection) within 8 weeks or 5.5 half-lives, whichever is longer, of screening
- Co-existing condition requiring medications that alter vascular flow (e.g., nitrates, calcium channel blockers, ergot containing drugs) [Potential effects of antihypertensive and migraine medications will be discussed with the Sponsor]
- Comorbid autoimmune disorders including systemic lupus erythematosus
- Unable to undergo an MRI examination (e.g., presence of a pacemaker, defibrillator, or other implanted device such as anterior interbody cages, aneurysm clip or pedicle screws
- allergic to contrast agent
- tattoos [in area of examination if contains metallic pigment])
- or will likely require sedation for the procedure
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Etanercept
Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
|
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-29
Zeitfenster: Day 1 to Day 29
|
Percent change in transfer constant (Ktrans) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from study day 1 to study day 29.
Ktrans reflects contrast delivery (capillary blood flow) and transport across the vascular endothelium (capillary permeability-surface area product), with the dominant factor depending on whether delivery is flow or permeability limited.
A Ktrans value of zero indicates the absence of disease (ie, no leakage of the contrast agent into the synovial volume); therefore, an increase in this parameter indicates worsening disease (ie, greater permeability of the synovial membrane).
|
Day 1 to Day 29
|
Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-57
Zeitfenster: Day 1 to Day 57
|
Percent change in transfer constant (Ktrans) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from study day 1 to study day 57.
Ktrans reflects contrast delivery (capillary blood flow) and transport across the vascular endothelium (capillary permeability-surface area product), with the dominant factor depending on whether delivery is flow or permeability limited.
A Ktrans value of zero indicates the absence of disease (ie, no leakage of the contrast agent into the synovial volume); therefore, an increase in this parameter indicates worsening disease (ie, greater permeability of the synovial membrane).
|
Day 1 to Day 57
|
Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-85
Zeitfenster: Day 1 to Day 85
|
Percent change in transfer constant (Ktrans) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from study day 1 to study day 85.
Ktrans reflects contrast delivery (capillary blood flow) and transport across the vascular endothelium (capillary permeability-surface area product), with the dominant factor depending on whether delivery is flow or permeability limited.
A Ktrans value of zero indicates the absence of disease (ie, no leakage of the contrast agent into the synovial volume); therefore, increases in this parameter indicates worsening disease (ie, greater permeability of the synovial membrane).
|
Day 1 to Day 85
|
Percent Change in Synovial Initial Area Under the (Contrast-time) Curve (IAUC) From Days 1-29
Zeitfenster: Day 1 to Day 29
|
Percent change in the synovial initial area under the contrast-time curve (IAUC) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from Day 1 to Day 29.
IAUC reflects the contrast distribution volume (extravascular extracellular space) in addition to contrast delivery and transport across the vascular endothelium.
An IAUC value of zero indicates the absence of disease (ie, no leakage of the contrast agent into the synovial volume); therefore, an increase in this parameter indicates worsening disease (ie, greater permeability of the synovial membrane).
|
Day 1 to Day 29
|
Percent Change in the Synovial Initial Area Under the Contrast-Tme Curve (IAUC) From Days 1-57
Zeitfenster: Day 1 to Day 57
|
Percent change in the synovial initial area under the contrast-time curve (IAUC) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from Day 1 to Day 57.
IAUC reflects the contrast distribution volume (extravascular extracellular space) in addition to contrast delivery and transport across the vascular endothelium.
An IAUC value of zero indicates the absence of disease (ie, no leakage of the contrast agent into the synovial volume); therefore, an increase in this parameter indicates worsening disease (ie, greater permeability of the synovial membrane).
|
Day 1 to Day 57
|
Percent Change in the Synovial Initial Area Under the Contrast-Time Curve (IAUC) From Days 1-85
Zeitfenster: Day 1 to Day 85
|
Percent change in the synovial initial area under the contrast-time curve (IAUC) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from Day 1 to Day 85. IAUC reflects the contrast distribution volume (extravascular extracellular space) in addition to contrast delivery and transport across the vascular endothelium.
An IAUC value of zero indicates the absence of disease (ie, no leakage of the contrast agent into the synovial volume); therefore, an increase in this parameter indicates worsening disease (ie, greater permeability of the synovial membrane).
|
Day 1 to Day 85
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percent Change in Synovial Volume From Days 1-29
Zeitfenster: Day 1 to Day 29
|
Percent change in the synovial volume for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from Day 1 to Day 29.
Synovial volume was evaluated by image subtraction from the T1-weighted images pre-and post-administration of the contrast agent.
|
Day 1 to Day 29
|
Percent Change in Synovial Volume From Days 1-57
Zeitfenster: Day 1 to Day 57
|
Percent change in the synovial volume for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from Day 1 to Day 57.
Synovial volume was evaluated by image subtraction from the T1-weighted images pre-and post-administration of the contrast agent.
|
Day 1 to Day 57
|
Percent Change in Synovial Volume From Days 1-85
Zeitfenster: Day 1 to Day 85
|
Percent change in the synovial volume for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the wrist from Day 1 to Day 85. Synovial volume was evaluated by image subtraction from the T1-weighted images pre-and post-administration of the contrast agent.
|
Day 1 to Day 85
|
Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 29
Zeitfenster: Day -28 to Day 29
|
Difference in percent change between synovial transfer constant (Ktrans) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) from study day 1 to study day 29 and from study day -28 to study day 1.
|
Day -28 to Day 29
|
Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 57
Zeitfenster: Day -28 to Day 57
|
Difference in percent change between synovial transfer constant (Ktrans) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) from study day 1 to study day 57 and from study day -28 to study day 1.
|
Day -28 to Day 57
|
Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 85
Zeitfenster: Day -28 to Day 85
|
Difference in percent change between synovial transfer constant (Ktrans) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) from study day 1 to study day 85 and from study day -28 to study day 1
|
Day -28 to Day 85
|
Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 29
Zeitfenster: Day -28 to Day 29
|
Difference in percent change between the synovial initial area under the contrast-time curve (IAUC) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) from Day 1 to Day 29 and from Day -28 to Day 1
|
Day -28 to Day 29
|
Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 57
Zeitfenster: Day -28 to Day 57
|
Difference in percent change between the synovial initial area under the contrast-time curve (IAUC) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) from Day 1 to Day 57 and from Day -28 to Day 1
|
Day -28 to Day 57
|
Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 85
Zeitfenster: Day -28 to Day 85
|
Difference in percent change between the synovial initial area under the contrast-time curve (IAUC) for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) from Day 1 to Day 85 and from Day -28 to Day 1
|
Day -28 to Day 85
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen
- Gelenkerkrankungen
- Erkrankungen des Bewegungsapparates
- Rheumatische Erkrankungen
- Bindegewebserkrankungen
- Arthritis
- Arthritis, Rheuma
- Physiologische Wirkungen von Arzneimitteln
- Agenten des peripheren Nervensystems
- Analgetika
- Agenten des sensorischen Systems
- Entzündungshemmende Mittel, nichtsteroidal
- Analgetika, nicht narkotisch
- Entzündungshemmende Mittel
- Antirheumatika
- Immunsuppressive Mittel
- Immunologische Faktoren
- Magen-Darm-Mittel
- Etanercept
Andere Studien-ID-Nummern
- 20060118
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Rheumatoide Arthritis
-
CEN BiotechMYEXPRESIONRekrutierungPolyarthritis; RheumatoidFrankreich
-
Centre Hospitalier Universitaire, AmiensUnbekanntMethotrexat | Polyarthritis; RheumatoidFrankreich
-
Chang Gung Memorial HospitalNoch keine RekrutierungArthritis-Knie | Arthritis HüfteTaiwan
-
Centocor, Inc.AbgeschlossenRheumatoide Arthritis, Jugendliche
-
Saint Alphonsus Regional Medical CenterAbgeschlossenArthritis-Knie | Arthritis der HüfteVereinigte Staaten
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; University of TorontoAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossenJuvenile idiopathische Arthritis | Arthritis, septisch | Arthritis, nicht näher bezeichnetFrankreich
-
University of Alabama at BirminghamNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) und andere MitarbeiterAbgeschlossen
-
AmgenBeendetJuvenile rheumatoide Arthritis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)AbgeschlossenJuvenile rheumatoide ArthritisVereinigte Staaten
Klinische Studien zur Etanercept
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Abgeschlossen
-
AmgenAbgeschlossenArthritis, Rheuma; Arthritis, PsoriasisVereinigte Staaten, Puerto Rico
-
AmgenAbgeschlossen
-
AmgenAbgeschlossen
-
Sun Yat-sen UniversityAbgeschlossen
-
Sun Pharmaceutical Industries LimitedZurückgezogen
-
All India Institute of Medical Sciences, New DelhiAbgeschlossen
-
Sun Pharmaceutical Industries LimitedAbgeschlossen
-
PfizerAbgeschlossenMittelschwere bis schwere PsoriasisKorea, Republik von
-
PfizerAbgeschlossen